Reduced Humoral and Cellular Immune Response to Primary COVID-19 mRNA Vaccination in Kidney Transplanted Children Aged 5-11 Years

Viruses. 2023 Jul 14;15(7):1553. doi: 10.3390/v15071553.

Abstract

The situation of limited data concerning the response to COVID-19 mRNA vaccinations in immunocom-promised children hinders evidence-based recommendations. This prospective observational study investigated humoral and T cell responses after primary BNT162b2 vaccination in secondary immunocompromised and healthy children aged 5-11 years. Participants were categorized as: children after kidney transplantation (KTx, n = 9), proteinuric glomerulonephritis (GN, n = 4) and healthy children (controls, n = 8). Expression of activation-induced markers and cytokine secretion were determined to quantify the T cell response from PBMCs stimulated with peptide pools covering the spike glycoprotein of SARS-CoV-2 Wuhan Hu-1 and Omicron BA.5. Antibodies against SARS-CoV-2 spike receptor-binding domain were quantified in serum. Seroconversion was detected in 56% of KTx patients and in 100% of the GN patients and controls. Titer levels were significantly higher in GN patients and controls than in KTx patients. In Ktx patients, the humoral response increased after a third immunization. No differences in the frequency of antigen-specific CD4+ and CD8+ T cells between all groups were observed. T cells showed a predominant anti-viral capacity in their secreted cytokines; however, this capacity was reduced in KTx patients. This study provides missing evidence concerning the humoral and T cell response in immunocompromised children after COVID-19 vaccination.

Keywords: SARS-CoV-2; T cell; glomerulonephritis; pediatric; solid organ transplant.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral
  • BNT162 Vaccine
  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Child
  • Humans
  • Immunity, Cellular
  • Immunity, Humoral
  • Kidney
  • Kidney Transplantation*
  • RNA, Messenger / genetics
  • SARS-CoV-2
  • Vaccination

Substances

  • BNT162 Vaccine
  • COVID-19 Vaccines
  • RNA, Messenger
  • Antibodies, Viral

Grants and funding

This research received no external funding. We acknowledge financial support regarding the article processing costs from the Open Access Publication Fund of UKE–University Medical Center Hamburg-Eppendorf and DFG–German Research Foundation Individual grants from the German Centre for Infection Research (DZIF; financed by the German Ministry of Education and Research, BMBF; partner-site Hamburg-Lübeck-Borstel-Riems) and from the iSTAR program (financed by the BMBF, 01EO2106) have supported the work of J.P., R.B. and N.T. received funding by the German Federal Ministry of Education and Research as part of the coverCHILD project of the Network University Medicine (NUM) (FKZ 01KX2121).